Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Tradeweb Markets heads into its October 29 earnings report on the strongest weekly footing in months, up 6.9% on the week to $107.54, while the Street is quietly warming to a name that spent most of the summer under a cloud of target-price cuts.
The most telling development this week came from the analyst community. Wells Fargo initiated coverage on October 2 with an Overweight and a $118 target, adding fresh conviction to a stock where the prevailing mood through July was one of retreat. Barclays followed today by lifting its target to $116 from $113, even while keeping its Equal-Weight rating. Those two moves represent a meaningful shift in tone after a brutal summer: JPMorgan cut its target from $143 to $117 in two steps between mid-July and early August, Morgan Stanley dropped from $138 to $122, and Piper Sandler trimmed to $102. The Street's consensus price target is now $123.53 against a current price of $107.54, implying about 15% upside. UBS holds the most bullish published view at $145, though that target was set in September, before the Q2 reaction had fully digested. The bull case centres on Tradeweb's fixed-income franchise capturing structural volume growth and the operating leverage that comes with it. The bear case is more about rate-sensitivity and the regulatory overhead of running electronic trading platforms under CFTC and MiFID II mandates.
Short interest is a sideshow here, not the story. Bears hold just under 3% of the free float, a figure that has drifted down roughly 12% over the past month. The borrow market reflects that lack of conviction: availability is essentially uncapped, with more than 113 million shares available against 3.4 million shorted. Cost to borrow has fallen 44% on the week to 0.44%, though it has been volatile, briefly spiking to 1.5% on September 28 before retreating. The ORTEX short score sits at 32.9, in the lower third of the universe, consistent with a stock where short sellers are not pressing a thesis. Positioning looks comfortable rather than aggressive on either side.
Options traders have pivoted more noticeably. The put/call ratio has more than tripled over the past two weeks, from around 0.13 in late September to 0.39 now, roughly 1.5 standard deviations above the 20-day average of 0.23. That shift is worth watching in context: the 52-week high on the PCR is 1.39, so this is not yet a defensive extreme, but the direction is clear. Some of the move likely reflects hedging ahead of the October 29 print. The last earnings day was a rough one. Tradeweb fell 7.1% on July 30 and was still down 4.5% five days later. Options buyers are paying attention.
The ownership picture is dominated by London Stock Exchange Group's 45.9% strategic stake, filed under a Schedule 13D/A through its Refinitiv Parent Limited vehicle. That is an activist filing on the register, and at over 50% of class as of the March 2025 disclosure, it means LSEG effectively controls the outcome of any major corporate decision. Positions are as last disclosed around the 5% threshold and a holder dropping below that level may not refile. T. Rowe Price holds 9.3% and added 1.3 million shares in the most recent period, making it the most active buyer among the large institutional names. Carmignac added 1.6 million shares through June, and Wellington added 412,000 through August, while The Vanguard Group filed a 13G/A in March showing it had reduced to zero from a prior 10.1% stake, with its successor Vanguard entities now each holding just over 5% separately.
Wikipedia attention for Tradeweb is running about 1.7 standard deviations above its own 90-day average, a signal that retail interest in the name is elevated relative to its own history, though there are no measured leading indicators in the alt data to connect that attention to the revenue line. The next earnings print on October 29 is therefore less about whether electronic fixed-income volumes are growing and more about whether Q3 growth landed close enough to analyst expectations to rebuild confidence after a summer of target reductions.
See the live data behind this article on ORTEX.
Open TW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
